ATE316088T1 - Tyrosin-kinase inhibitoren - Google Patents
Tyrosin-kinase inhibitorenInfo
- Publication number
- ATE316088T1 ATE316088T1 AT02744810T AT02744810T ATE316088T1 AT E316088 T1 ATE316088 T1 AT E316088T1 AT 02744810 T AT02744810 T AT 02744810T AT 02744810 T AT02744810 T AT 02744810T AT E316088 T1 ATE316088 T1 AT E316088T1
- Authority
- AT
- Austria
- Prior art keywords
- tyrosine kinase
- compounds
- kinase inhibitors
- present
- atherosclerosis
- Prior art date
Links
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 abstract 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30024501P | 2001-06-22 | 2001-06-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE316088T1 true ATE316088T1 (de) | 2006-02-15 |
Family
ID=23158280
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02744810T ATE316088T1 (de) | 2001-06-22 | 2002-06-18 | Tyrosin-kinase inhibitoren |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6875767B2 (de) |
| EP (1) | EP1404672B1 (de) |
| JP (1) | JP2004535437A (de) |
| AT (1) | ATE316088T1 (de) |
| AU (1) | AU2002346053B2 (de) |
| CA (1) | CA2450562A1 (de) |
| DE (1) | DE60208792T2 (de) |
| ES (1) | ES2255621T3 (de) |
| WO (1) | WO2003000687A1 (de) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7265134B2 (en) | 2001-08-17 | 2007-09-04 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO2003092595A2 (en) | 2002-05-02 | 2003-11-13 | Merck & Co., Inc | Tyrosine kinase inhibitors |
| WO2005098448A2 (en) * | 2004-03-26 | 2005-10-20 | Merck & Co., Inc. | Method and biomarkers for detecting tumor endothelial cell proliferation |
| EA011671B1 (ru) * | 2004-06-04 | 2009-04-28 | Арена Фармасьютикалз, Инк. | Замещенные производные арила и гетероарила в качестве модуляторов метаболизма и для профилактики и лечения связанных с ним расстройств |
| SI1768657T1 (sl) * | 2004-06-23 | 2009-02-28 | Sirion Terapeutics Inc | Postopki in sestavki za zdravljenje oftalmičnih obolenj z derivati retinila |
| JP2008519054A (ja) * | 2004-11-04 | 2008-06-05 | シリオン セラピューティクス， インコーポレイテッド | レチノール−レチノール結合タンパク質（ｒｂｐ）−トランスチレチン（ｔｔｒ）複合体の形成のモジュレーター |
| CA2638753A1 (en) * | 2004-12-08 | 2006-06-15 | Sirion Therapeutics, Inc. | Methods, assays and compositions for treating retinol-related diseases |
| WO2006129842A1 (ja) * | 2005-06-01 | 2006-12-07 | Banyu Pharmaceutical Co., Ltd. | オーロラa選択的阻害作用を有する新規アミノピリジン誘導体 |
| US8440217B1 (en) | 2005-06-15 | 2013-05-14 | Mawaheb M. EL-Naggar | Method and system with contact lens product for treating and preventing adverse eye conditions |
| UA81382C2 (en) * | 2005-07-11 | 2007-12-25 | Composition for treating retinol-related diseases by modulation of retinol binding | |
| CA2637172A1 (en) * | 2006-01-27 | 2007-08-09 | Array Biopharma Inc. | Pyridin-2-amine derivatives and their use as glucokinase activators |
| WO2007097839A2 (en) * | 2006-02-16 | 2007-08-30 | Massachusetts Eye And Ear Infirmary | Ansamycin analogs or heat shock 90 inhibitors in combination with pdt treatin conditions of the eye |
| US8296521B2 (en) * | 2006-06-30 | 2012-10-23 | Mosaid Technologies Incorporated | Method of configuring non-volatile memory for a hybrid disk drive |
| US8246966B2 (en) * | 2006-08-07 | 2012-08-21 | University Of Georgia Research Foundation, Inc. | Trypanosome microsome system and uses thereof |
| WO2008066755A2 (en) * | 2006-11-22 | 2008-06-05 | University Of Georgia Research Foundation, Inc. | Tyrosine kinase inhibitors as anti-kinetolastid and anti-apicomplexan agents |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| WO2008124757A1 (en) * | 2007-04-10 | 2008-10-16 | Bristol-Myers Squibb Company | Thiazolyl compounds useful as kinase inhibitors |
| AU2008305294B2 (en) | 2007-09-21 | 2012-11-29 | Array Biopharma Inc. | Pyridin-2 -yl-amino-1, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus |
| SMT201700293T1 (it) | 2009-07-20 | 2017-07-18 | Bristol Myers Squibb Co | Combinazione di un anticorpo anti-ctla-4 con etoposide per il trattamento sinergico di malattie proliferative |
| MX337666B (es) | 2009-10-20 | 2016-03-14 | Nestec Sa | Ensayos regulados mediante proximidad para detectar proteinas de fusion oncogenicas. |
| SG192270A1 (en) | 2011-02-17 | 2013-08-30 | Nestec Sa | Apparatus and method for isolating leukocytes and tumor cells by filtration |
| AU2013255511B2 (en) | 2012-05-04 | 2016-01-28 | Pfizer Inc. | Prostate-associated antigens and vaccine-based immunotherapy regimens |
| PE20160671A1 (es) | 2013-08-02 | 2016-07-09 | Pfizer | Anticuerpos anti-cxcr4 y conjugados de anticuerpo y farmaco |
| WO2016063122A1 (en) | 2014-10-20 | 2016-04-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for screening a subject for a cancer |
| JP6864953B2 (ja) | 2014-12-09 | 2021-04-28 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Ａｘｌに対するヒトモノクローナル抗体 |
| WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
| US20180201687A1 (en) | 2015-07-07 | 2018-07-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to myosin 18a and uses thereof |
| WO2017032867A1 (en) | 2015-08-27 | 2017-03-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the survival time of patients suffering from a lung cancer |
| WO2017055326A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of myeloid dendritic cells in a tissue sample |
| WO2017055322A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of neutrophils in a tissue sample |
| WO2017055324A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of cells of monocytic origin in a tissue sample |
| WO2017055327A1 (en) | 2015-09-29 | 2017-04-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of endothelial cells in a tissue sample |
| US20230183346A1 (en) | 2016-02-26 | 2023-06-15 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antibodies having specificity for btla and uses thereof |
| CN109689089A (zh) | 2016-05-25 | 2019-04-26 | 国家医疗保健研究所 | 治疗癌症的方法和组合物 |
| WO2018011166A2 (en) | 2016-07-12 | 2018-01-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for quantifying the population of myeloid dendritic cells in a tissue sample |
| BR112019001693A2 (pt) | 2016-07-29 | 2019-07-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | anticorpos direcionados a macrófagos associados a tumores e seus usos |
| ES2883678T3 (es) | 2016-10-21 | 2021-12-09 | Inst Nat Sante Rech Med | Métodos para promover la respuesta de linfocitos T |
| WO2018087391A1 (en) | 2016-11-14 | 2018-05-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for modulating stem cells proliferation or differentiation |
| US11274160B2 (en) | 2017-03-02 | 2022-03-15 | INSERM (Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to Nectin-4 and uses thereof |
| WO2018185516A1 (en) | 2017-04-05 | 2018-10-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cardiovascular toxicity induced by anti-cancer therapy |
| WO2018189403A1 (en) | 2017-04-14 | 2018-10-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancer |
| JP7323457B2 (ja) | 2017-05-18 | 2023-08-08 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 肥満細胞疾患の処置のための方法及び医薬組成物 |
| WO2019072885A1 (en) | 2017-10-11 | 2019-04-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | MAGNETIC NANOPARTICLES FOR THE TREATMENT OF CANCER |
| WO2019072888A1 (en) | 2017-10-11 | 2019-04-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | METHODS OF PREDICTING THE THERAPEUTIC RESPONSE IN HEPATOCELLULAR CANCER |
| KR20250008153A (ko) | 2017-11-24 | 2025-01-14 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 암 치료를 위한 방법 및 조성물 |
| US11814686B2 (en) | 2017-12-07 | 2023-11-14 | Institut National de la Santéde la Recherche Médicale | Method for screening and treating a subject for a cancer |
| WO2019185683A1 (en) | 2018-03-28 | 2019-10-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cancer |
| JP2021521445A (ja) | 2018-04-13 | 2021-08-26 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 前立腺癌又は乳癌を患っている患者の転帰を予測するための及び処置のための方法 |
| WO2019211369A1 (en) | 2018-05-03 | 2019-11-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cancer |
| WO2019211370A1 (en) | 2018-05-03 | 2019-11-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cancer |
| WO2019229115A1 (en) | 2018-05-30 | 2019-12-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treating cancer |
| WO2019234221A1 (en) | 2018-06-08 | 2019-12-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for stratification and treatment of a patient suffering from chronic lymphocytic leukemia |
| WO2020030634A1 (en) | 2018-08-06 | 2020-02-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating cancers |
| EP3849602A1 (de) | 2018-09-10 | 2021-07-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Kombination eines her2/neu-antikörpers mit häm zur behandlung von krebs |
| WO2020165370A1 (en) | 2019-02-13 | 2020-08-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for selecting a cancer treatment in a subject suffering from cancer |
| WO2020178400A1 (en) | 2019-03-06 | 2020-09-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to diagnose a cmmrd |
| EP3972997A1 (de) | 2019-05-20 | 2022-03-30 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Neuartige anti-cd25-antikörper |
| US20220290244A1 (en) | 2019-08-02 | 2022-09-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for screening a subject for a cancer |
| EP3800201A1 (de) | 2019-10-01 | 2021-04-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cd28h-stimulierung verbessert nk-zellen-abtötungsaktivitäten |
| US12577324B2 (en) | 2019-12-09 | 2026-03-17 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Antibodies having specificity to HER4 and uses thereof |
| JP2023525053A (ja) | 2020-05-12 | 2023-06-14 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | 皮膚ｔ細胞リンパ腫及びｔｆｈ由来リンパ腫を処置する新しい方法 |
| WO2022101463A1 (en) | 2020-11-16 | 2022-05-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of the last c-terminal residues m31/41 of zikv m ectodomain for triggering apoptotic cell death |
| CN117412765A (zh) | 2021-01-29 | 2024-01-16 | 国立卫生研究所 | 诊断msi癌症的方法 |
| US20220389104A1 (en) | 2021-05-28 | 2022-12-08 | Ose Immunotherapeutics | Method for Treating CD127-Positive Cancers by Administering an Anti-CD127 Agent |
| CN115160340B (zh) * | 2022-06-07 | 2023-07-21 | 四川大学华西医院 | 一种具有ack1抑制活性的小分子化合物及其应用 |
| EP4584291A1 (de) | 2022-09-08 | 2025-07-16 | Institut National de la Santé et de la Recherche Médicale | Antikörper mit spezifität gegen ltbp2 und verwendungen davon |
| WO2024061930A1 (en) | 2022-09-22 | 2024-03-28 | Institut National de la Santé et de la Recherche Médicale | New method to treat and diagnose peripheral t-cell lymphoma (ptcl) |
| WO2024127053A1 (en) | 2022-12-14 | 2024-06-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method to predict a response to immune checkpoint inhibitors in patient with msi cancer |
| WO2024161015A1 (en) | 2023-02-03 | 2024-08-08 | Institut National de la Santé et de la Recherche Médicale | Method to treat age-related diseases |
| WO2025012417A1 (en) | 2023-07-13 | 2025-01-16 | Institut National de la Santé et de la Recherche Médicale | Anti-neurotensin long fragment and anti-neuromedin n long fragment antibodies and uses thereof |
| WO2025073890A1 (en) | 2023-10-06 | 2025-04-10 | Institut National de la Santé et de la Recherche Médicale | Method to capture circulating tumor extracellular vesicles |
| WO2025114411A1 (en) | 2023-11-29 | 2025-06-05 | Institut National de la Santé et de la Recherche Médicale | New method to treat brain or neurologic disorders |
| WO2025171035A1 (en) * | 2024-02-06 | 2025-08-14 | Corvus Pharmaceuticals, Inc. | Itk inhibitors and uses thereof |
| WO2025224297A1 (en) | 2024-04-26 | 2025-10-30 | Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to tgfbi and uses thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4649146A (en) | 1983-01-31 | 1987-03-10 | Fujisawa Pharmaceutical Co., Ltd. | Thiazole derivatives and pharmaceutical composition comprising the same |
| US4876252A (en) | 1986-01-13 | 1989-10-24 | American Cyanamid Company | 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines |
| US4788195A (en) | 1986-01-13 | 1988-11-29 | American Cyanamid Company | 4,5,6-substituted-N-(substituted-phenyl)-2-pyrimidinamines |
| JPH0753666B2 (ja) | 1987-09-14 | 1995-06-07 | 久光製薬株式会社 | 置換ジフェニルチアゾール誘導体からなる抗炎症剤 |
| DE3905763A1 (de) | 1989-02-24 | 1990-09-06 | Bayer Ag | Sulfonylierte azinyliminoheteroazole, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung als herbizide |
| US6192347B1 (en) * | 1992-10-28 | 2001-02-20 | Graff/Ross Holdings | System and methods for computing to support decomposing property into separately valued components |
| DE4124942A1 (de) | 1991-07-27 | 1993-01-28 | Thomae Gmbh Dr K | 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| TW225528B (de) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| WO1994001423A1 (fr) | 1992-07-07 | 1994-01-20 | Nippon Soda Co., Ltd. | Derive de thiazol |
| US5516775A (en) | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
| JPH08503971A (ja) | 1993-10-01 | 1996-04-30 | チバ−ガイギー アクチェンゲゼルシャフト | ピリミジンアミン誘導体及びその調製のための方法 |
| US5543520A (en) | 1993-10-01 | 1996-08-06 | Ciba-Geigy Corporation | Pyrimidine derivatives |
| JPH07149745A (ja) | 1993-11-30 | 1995-06-13 | Hisamitsu Pharmaceut Co Inc | 新規な２−アミノチアゾール誘導体 |
| US5530000A (en) * | 1993-12-22 | 1996-06-25 | Ortho Pharmaceutical Corporation | Substituted pyrimidinylaminothiazole derivatives useful as platelet aggreggation inhibitors |
| JPH10501806A (ja) | 1994-06-22 | 1998-02-17 | ブリティッシュ バイオテック ファーマシューティカルズ リミテッド | 金属タンパク質分解酵素阻害剤 |
| GB9523675D0 (en) | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| DE19548415A1 (de) | 1995-12-22 | 1997-06-26 | Bayer Ag | 1-Aryl-3-halogenalkyl-5-arylaminotriazole |
| US5952331A (en) | 1996-05-23 | 1999-09-14 | Syntex (Usa) Inc. | Aryl pyrimidine derivatives |
| TW440563B (en) | 1996-05-23 | 2001-06-16 | Hoffmann La Roche | Aryl pyrimidine derivatives and a pharmaceutical composition thereof |
| US5958934A (en) | 1996-05-23 | 1999-09-28 | Syntex (U.S.A.) Inc. | Aryl pyrimidine derivatives and uses thereof |
| KR20000070568A (ko) * | 1997-01-28 | 2000-11-25 | 폴락 돈나 엘. | 당뇨병 및 비만 치료를 위한 β3 효능제로서의 티아졸 벤젠설폰아미드 |
| NZ503788A (en) * | 1997-10-27 | 2002-11-26 | Agouron Pharma | 4-aminothiazole derivatives and their use as inhibitors of cyclin-dependent kinases |
| DE19824175A1 (de) | 1998-05-29 | 1999-12-02 | Novartis Ag | Amino-azol-Verbindungen |
| AU4506399A (en) | 1998-06-05 | 1999-12-30 | Novartis Ag | Aryl pyridinyl thiazoles |
| CA2332325A1 (en) * | 1998-06-18 | 1999-12-23 | Bristol-Myers Squibb Company | Carbon substituted aminothiazole inhibitors of cyclin dependent kinases |
| ATE459616T1 (de) | 1998-08-11 | 2010-03-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
| US6184226B1 (en) | 1998-08-28 | 2001-02-06 | Scios Inc. | Quinazoline derivatives as inhibitors of P-38 α |
| US6167384A (en) * | 1998-09-01 | 2000-12-26 | Graff/Ross Holdings | Augmented system and methods for computing to support fractional contingent interests in property |
| PL215901B1 (pl) | 1999-04-15 | 2014-02-28 | Bristol Myers Squibb Co | Cykliczny inhibitor bialkowych kinaz tyrozynowych, jego zastosowanie oraz kompozycja farmaceutyczna zawierajaca taki zwiazek |
| DE60023926T2 (de) * | 1999-09-10 | 2006-07-20 | Merck & Co., Inc. | Tyrosin kinase inhibitoren |
| WO2001056567A1 (en) * | 2000-02-04 | 2001-08-09 | Novo Nordisk A/S | 2,4-diaminothiazole derivatives and their use as glycogen synthase kinase-3 (gsk-3) inhibitors |
| MY123585A (en) * | 2000-03-23 | 2006-05-31 | Merck Canada Inc | Tri-aryl-substituted-ethane pde4 inhibitors. |
| US7555451B2 (en) * | 2001-05-17 | 2009-06-30 | Microsoft Corporation | Cash flow forecasting |
-
2002
- 2002-06-18 AT AT02744810T patent/ATE316088T1/de not_active IP Right Cessation
- 2002-06-18 AU AU2002346053A patent/AU2002346053B2/en not_active Ceased
- 2002-06-18 ES ES02744810T patent/ES2255621T3/es not_active Expired - Lifetime
- 2002-06-18 DE DE60208792T patent/DE60208792T2/de not_active Expired - Fee Related
- 2002-06-18 EP EP02744810A patent/EP1404672B1/de not_active Expired - Lifetime
- 2002-06-18 CA CA002450562A patent/CA2450562A1/en not_active Abandoned
- 2002-06-18 WO PCT/US2002/021110 patent/WO2003000687A1/en not_active Ceased
- 2002-06-18 JP JP2003507090A patent/JP2004535437A/ja active Pending
- 2002-06-19 US US10/174,774 patent/US6875767B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2002346053B2 (en) | 2008-03-13 |
| JP2004535437A (ja) | 2004-11-25 |
| ES2255621T3 (es) | 2006-07-01 |
| EP1404672B1 (de) | 2006-01-18 |
| EP1404672A1 (de) | 2004-04-07 |
| CA2450562A1 (en) | 2003-01-03 |
| DE60208792T2 (de) | 2006-08-31 |
| WO2003000687A1 (en) | 2003-01-03 |
| DE60208792D1 (de) | 2006-04-06 |
| US6875767B2 (en) | 2005-04-05 |
| US20030100567A1 (en) | 2003-05-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60208792D1 (de) | Tyrosin-kinase inhibitoren | |
| ATE368457T1 (de) | Tyrosinkinase inhibitoren | |
| NO20021166D0 (no) | Tyrosinkinase-inhibitorer | |
| EP1226119A4 (de) | Tyrosin kinase inhibitoren | |
| DE60318198D1 (de) | Tyrosinkinase-hemmer | |
| YU28602A (sh) | Inhibitori tirozin kinaze | |
| WO2002045652A3 (en) | Tyrosine kinase inhibitors | |
| WO2003037252A3 (en) | Tyrosine kinase inhibitors | |
| AU2687702A (en) | Orally active salts with tyrosine kinase activity | |
| WO2004052315A3 (en) | Tyrosine kinase inhibitors | |
| WO2004052286A3 (en) | Tyrosine kinase inhibitors | |
| WO2004041164A3 (en) | Kinase inhibitors | |
| WO2003088900A3 (en) | Solid forms of salts with tyrosine kinase activity | |
| DE60231439D1 (de) | Mitotische kinesinhemmer | |
| DE60234278D1 (de) | Mitotische kinesin-hemmer | |
| DE60215682D1 (de) | AZAOXOINDOL DERIVATE ALS Trk PROTEIN KINASE HEMMSTOFFE ZUR BEHANDLUNG VON KREBS UND CHRONISCHEM SCHMERZ | |
| WO2003020699A3 (en) | Tyrosine kinase inhibitors | |
| CA3139156A1 (en) | Compounds for the treatment of kinase-dependent disorders | |
| ATE424208T1 (de) | Proteinkinaseinhibitoren | |
| WO2003015717A3 (en) | Tyrosine kinase inhibitors | |
| ECSP003729A (es) | Inhibidores de la tirosina quinasa | |
| ATE540951T1 (de) | Substituierte 7,8-dihydro-1h-pyrimidoä4,5- büdiazepin-4-amine als kinase inhibitoren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |